Vaginal atrophy How Blissel works Dosing Useful resources FAQs Blissel API Back to main site

BlisselⓇ is simply dosed for both initial and maintenance therapy

How to start therapy and maintenance¹

BlisselⓇ can be started any time after the manifestation of symptoms.

Initial treatment:

One applicator-dose of vaginal gel per day for 3 weeks (suitably at bedtime).

Maintenance treatment:

One applicator-dose of vaginal gel twice a week (suitably at bedtime) is recommended. An evaluation of treatment continuation after 12 weeks should be carried out by the physician.

For initiation and continuation of treatment of post-menopausal symptoms, the lowest effective dose for the shortest duration should be used.

For oestrogen products for vaginal application of which the systemic exposure to the oestrogen remains within the normal postmenopausal range, it is not recommended to add a progestagen.

Missed doses¹

A missed dose should be administered as soon as remembered, unless it is more than 12 hours overdue. In the latter case the missed dose should be skipped, and the next dose should be administered at the normal time.

See the summary of product characteristics for full prescribing information.¹

Precautions ¹

For the treatment of postmenopausal symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and HRT should only be continued as long as the benefit outweighs the risk.
Blissel^Ⓡ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.

For full information see the summary of product characteristics.^1.

Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Summary of Product Characteristics can be found at www.medicines.ie

Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie.

Adverse events should also be reported to Consilient Health at [email protected] or 012057766. The information on this website is intended for Health Care Professional who practice in the Republic of Ireland only

The information on this website is intended for Republic of Ireland residents only.
IE-BLS-655 Date of Preparation September 2025

Provide Feedback

(function(t,e,s,n){var o,a,c;t.SMCX=t.SMCX||[],e.getElementById(n)||(o=e.getElementsByTagName(s),a=o[o.length-1],c=e.createElement(s),c.type="text/javascript",c.async=!0,c.id=n,c.src="https://widget.surveymonkey.com/collect/website/js/tRaiETqnLgj758hTBazgdws7k5QmnfCdd2cjjySZdrIUgzqN1wKhsoc33uvarp3E.js",a.parentNode.insertBefore(c,a))})(window,document,"script","smcx-sdk"); Create your own user feedback survey

You are now leaving consilienthealth.ie

BlisselⓇ is simply dosed for both initial and maintenance therapy

How to start therapy and maintenance1